Loading
Gut bacteria appear to influence whether immunotherapy works, and diet and antibiotics shape gut bacteria. Yet almost no drug trial records what patients ate or which antibiotics they took. Recording it would cost almost nothing.
Fibre intake, probiotic use, antibiotics and proton-pump inhibitors are each associated with checkpoint-inhibitor outcomes in observational cohorts, but the data come from single centres with recall questionnaires. Pivotal trials enrol tens of thousands of patients under protocol with concomitant medication logs already captured; adding a short validated diet screener and banking a baseline stool sample would generate the largest and cleanest dataset on host factors in immunotherapy, and allow stratified or covariate-adjusted analyses that could explain part of the variability in response.
Shares Gut microbiome diversity and composition, Dietary fibre and the gut microbiome for immunotherapy response, No one can predict who responds to immunotherapy, Renal cell carcinoma.
Shares Protect the gut flora of patients about to start immunotherapy, Test a high-fibre diet as an immunotherapy adjunct, Dietary fibre and the gut microbiome for immunotherapy response, Immune checkpoint inhibitors.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, No one can predict who responds to immunotherapy, Renal cell carcinoma, Melanoma.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, No one can predict who responds to immunotherapy, Renal cell carcinoma, Nivolumab.
Shares Gut microbiome diversity and composition, Probiotics, antibiotics and stewardship around immunotherapy, Dietary fibre and the gut microbiome for immunotherapy response, Renal cell carcinoma.
Shares Gut microbiome diversity and composition, No one can predict who responds to immunotherapy, Nivolumab, Melanoma.
Shares No one can predict who responds to immunotherapy, Nivolumab, Melanoma, Pembrolizumab.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, No one can predict who responds to immunotherapy, Renal cell carcinoma, Immune checkpoint inhibitors.